Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026.

The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s NVO Tresiba (insulin degludec) for 78 weeks in T2D patients who have switched from daily basal insulin injections.

Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

Novo Nordisk will lower the US list prices for Tresiba and Fiasp by more than 70% starting January 1, 2026, following the lowering of its other insulin products on January 1, 2024. The company ...

Its portfolio includes insulin analogs, GLP-1 receptor agonists, and oral antidiabetic drugs like Rybelsus, Ozempic, and Tresiba. Novo Nordisk A/S (NYSE:NVO) delivered exceptional financial ...